<p>Broadleaf Partners LLC 在第一季度将其在艾伯维公司（NYSE:ABBV - 免费报告）股票中的持股比例削减了 23.8%，根据该公司最近向证券交易委员会（SEC）披露的信息。该公司在季度内出售了 1,800 股后，持有 5,763 股该公司的股票。根据其最近的 SEC 文件，Broadleaf Partners LLC 在艾伯维的持股价值为 1,207,000 美元。</p>
<ul>
<li>艾伯维股票关注突破，管道和利润增长</li>
</ul>
<p>其他几家大型投资者最近也买卖了 ABBV 的股票。GAMMA Investing LLC 在第一季度将其在艾伯维的持仓提高了 25,841.6%。GAMMA Investing LLC 目前拥有 10,234,737 股该公司的股票，价值 2,144,382,000 美元，此前在上个季度又收购了 10,195,284 股。Nuveen LLC 在第一季度购买了艾伯维的新头寸，价值 1,819,154,000 美元。高盛集团在第一季度将其在艾伯维的持仓提高了 31.6%。高盛集团目前拥有 14,646,908 股该公司的股票，价值 3,068,820,000 美元，此前在上个季度又收购了 3,519,187 股。北方信托公司在第四季度将其在艾伯维的持仓提高了 11.8%。北方信托公司目前拥有 21,824,626 股该公司的股票，价值 3,878,236,000 美元，此前在上个季度又收购了 2,299,645 股。最后，德意志银行在第四季度将其在艾伯维的持仓提高了 27.4%。德意志银行目前拥有 9,769,102 股该公司的股票，价值 1,735,969,000 美元，此前在上个季度又收购了 2,102,273 股。对冲基金和其他机构投资者拥有该公司 70.23% 的股票。</p>
<h2>艾伯维的内部交易</h2>
<p>在其他新闻中，执行副总裁 Azita Saleki-Gerhardt 在 8 月 12 日（星期二）出售了 42,370 股该公司的股票。股票以平均价格 198.42 美元出售，总交易额为 8,407,055.40 美元。交易完成后，该执行副总裁持有 177,292 股该公司的股票，价值 35,178,278.64 美元。这代表其持仓减少了 19.29%。该交易在 SEC 的法律文件中披露，相关信息可通过此链接获取。此外，执行副总裁 Nicholas Donoghoe 在 8 月 5 日（星期二）出售了 13,295 股该公司的股票。股票以平均价格 198.51 美元出售，总交易额为 2,639,190.45 美元。交易后，该执行副总裁直接持有 58,247 股该公司的股票，价值约 11,562,611.97 美元。这代表其持仓减少了 18.58%。该销售的披露信息可在此找到。公司内部人士持有该公司 0.25% 的股票。</p>
<h2>艾伯维股票上涨 0.4%</h2>
<ul>
<li>3 家生物科技巨头受益于美国销售和政策变化</li>
</ul>
<p>艾伯维股票在周五开盘价为 210.2840 美元。该股票的市值为 3714.8 亿美元，市盈率为 100.14，市盈增长比率为 1.35，贝塔值为 0.50。该股票的 50 日移动平均价格为 192.84 美元，200 日移动平均价格为 192.96 美元。艾伯维公司的 52 周最低价为 163.81 美元，52 周最高价为 218.66 美元。该公司的流动比率为 0.74，速动比率为 0.61，债务与股本比率为 44.14。</p>
<p>艾伯维（NYSE:ABBV - 获取免费报告）最近在 7 月 31 日（星期四）发布了季度财报。该公司报告季度每股收益为 2.97 美元，低于分析师一致预期的 3.24 美元（差额为 0.27 美元）。该公司季度收入为 154.2 亿美元，而分析师预期为 149.3 亿美元。艾伯维的股本回报率为 699.66%，净利润率为 6.45%。该公司季度收入较去年同期增长了 6.6%。在去年同期，该公司每股收益为 2.65 美元。股票研究分析师预测，艾伯维公司本财年的每股收益将达到 12.31 美元。</p>
<h2>艾伯维分红公告</h2>
<ul>
<li>如果你想购买艾伯维但没有，现在仍然有时间购买</li>
</ul>
<p>该公司最近还披露了季度分红，已于 8 月 15 日（星期五）支付。7 月 15 日（星期二）登记在册的股东获得每股 1.64 美元的分红。该分红的除息日期为 7 月 15 日（星期二）。这代表年化分红为 6.56 美元，分红收益率为 3.1%。艾伯维的分红支付比率目前为 312.38%。</p>
<h2>分析师评级变动</h2>
<p>几位研究分析师对该公司发布了报告。大和美国在 8 月 7 日（星期四）的研究报告中将艾伯维的评级从 “持有” 上调至 “强力买入”。大和资本市场在 8 月 7 日（星期四）的研究报告中将艾伯维的评级从 “中性” 上调至 “跑赢大盘”，并为该公司设定了 214.00 美元的目标价。派珀·桑德勒在 8 月 12 日（星期二）的研究报告中开始覆盖艾伯维。他们给予 “增持” 评级，并为该公司设定了 231.00 美元的目标价。美国银行在 6 月 9 日（星期一）将艾伯维的目标价上调至 204.00 美元，并给予该公司 “持有” 评级。最后，花旗集团在 6 月 11 日（星期三）将艾伯维的目标价上调至 205.00 美元，并给予该公司 “持有” 评级。五位股票研究分析师对该股票给予了强力买入评级，十六位给予了买入评级，六位给予了持有评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 214.95 美元。</p>
<p><strong>阅读我们关于艾伯维的最新研究报告</strong></p>
<h2>艾伯维公司简介</h2>
<p>（免费报告）</p>
<p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供的药物包括：Humira，用于治疗自身免疫性疾病和肠道贝赫切特病以及脓疱性坏死性皮肤病；Skyrizi，用于治疗中度至重度斑块型银屑病、银屑病性关节炎和克罗恩病；Rinvoq，用于治疗类风湿性关节炎、银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica，用于治疗成人血癌患者；Epkinly，用于治疗淋巴瘤；Elahere，用于治疗癌症；Venclexta/Venclyxto，用于治疗血癌。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比艾伯维更好的股票</li>
<li>支撑与阻力的基础知识</li>
<li>等权重 ETF：当今市场的隐藏上行空间</li>
<li>5 只值得考虑的高评级分红股票</li>
<li>Zillow Group 接近关键技术水平：是时候买入了吗？</li>
<li>异常交易量的股票：如何实时找到异常交易量股票</li>
<li>真正的多元化：现在可以购买的 3 只股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
<p>在你考虑艾伯维之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前买入……而艾伯维并不在名单上。</p>
<p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

艾伯维

<p>Broadleaf Partners LLC 在第一季度减少了对艾伯维（AbbVie Inc.，NYSE:ABBV）23.8% 的持股，目前持有 5,763 股，价值 120 万美元。其他投资者，包括 GAMMA Investing LLC 和高盛，显著增加了他们的持仓。艾伯维股票开盘价为 210.28 美元，市值为 3714.8 亿美元。该公司报告第二季度每股收益为 2.97 美元，未达到预期，但收入同比增长 6.6%。艾伯维宣布每股季度股息为 1.64 美元，收益率为 3.1%</p>

<p>Broadleaf Partners LLC cut its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 23.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,763 shares of the company's stock after selling 1,800 shares during the quarter. Broadleaf Partners LLC's holdings in AbbVie were worth $1,207,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Broadleaf Partners LLC 在第一季度将其在艾伯维公司（NYSE:ABBV - 免费报告）股票中的持股比例削减了 23.8%，根据该公司最近向证券交易委员会（SEC）披露的信息。该公司在季度内出售了 1,800 股后，持有 5,763 股该公司的股票。根据其最近的 SEC 文件，Broadleaf Partners LLC 在艾伯维的持股价值为 1,207,000 美元。</p>
</div><ul>
<li>AbbVie Stock Eyes Breakout as Pipeline and Profits Grow</li>
</ul>
<div class="lb-trans"><ul>
<li>艾伯维股票关注突破，管道和利润增长</li>
</ul>
</div><p>Several other large investors have also recently bought and sold shares of ABBV. GAMMA Investing LLC raised its position in AbbVie by 25,841.6% in the first quarter. GAMMA Investing LLC now owns 10,234,737 shares of the company's stock worth $2,144,382,000 after acquiring an additional 10,195,284 shares in the last quarter. Nuveen LLC purchased a new position in AbbVie in the first quarter worth $1,819,154,000. Goldman Sachs Group Inc. raised its position in AbbVie by 31.6% in the first quarter. Goldman Sachs Group Inc. now owns 14,646,908 shares of the company's stock worth $3,068,820,000 after acquiring an additional 3,519,187 shares in the last quarter. Northern Trust Corp raised its position in AbbVie by 11.8% in the fourth quarter. Northern Trust Corp now owns 21,824,626 shares of the company's stock worth $3,878,236,000 after acquiring an additional 2,299,645 shares in the last quarter. Finally, Deutsche Bank AG raised its position in AbbVie by 27.4% in the fourth quarter. Deutsche Bank AG now owns 9,769,102 shares of the company's stock worth $1,735,969,000 after acquiring an additional 2,102,273 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company's stock.</p>
<div class="lb-trans"><p>其他几家大型投资者最近也买卖了 ABBV 的股票。GAMMA Investing LLC 在第一季度将其在艾伯维的持仓提高了 25,841.6%。GAMMA Investing LLC 目前拥有 10,234,737 股该公司的股票，价值 2,144,382,000 美元，此前在上个季度又收购了 10,195,284 股。Nuveen LLC 在第一季度购买了艾伯维的新头寸，价值 1,819,154,000 美元。高盛集团在第一季度将其在艾伯维的持仓提高了 31.6%。高盛集团目前拥有 14,646,908 股该公司的股票，价值 3,068,820,000 美元，此前在上个季度又收购了 3,519,187 股。北方信托公司在第四季度将其在艾伯维的持仓提高了 11.8%。北方信托公司目前拥有 21,824,626 股该公司的股票，价值 3,878,236,000 美元，此前在上个季度又收购了 2,299,645 股。最后，德意志银行在第四季度将其在艾伯维的持仓提高了 27.4%。德意志银行目前拥有 9,769,102 股该公司的股票，价值 1,735,969,000 美元，此前在上个季度又收购了 2,102,273 股。对冲基金和其他机构投资者拥有该公司 70.23% 的股票。</p>
</div><h2>Insider Transactions at AbbVie</h2>
<div class="lb-trans"><h2>艾伯维的内部交易</h2>
</div><p>In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the completion of the transaction, the executive vice president owned 177,292 shares of the company's stock, valued at $35,178,278.64. This represents a 19.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Nicholas Donoghoe sold 13,295 shares of the company's stock in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total transaction of $2,639,190.45. Following the transaction, the executive vice president directly owned 58,247 shares of the company's stock, valued at approximately $11,562,611.97. This represents a 18.58% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.25% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁 Azita Saleki-Gerhardt 在 8 月 12 日（星期二）出售了 42,370 股该公司的股票。股票以平均价格 198.42 美元出售，总交易额为 8,407,055.40 美元。交易完成后，该执行副总裁持有 177,292 股该公司的股票，价值 35,178,278.64 美元。这代表其持仓减少了 19.29%。该交易在 SEC 的法律文件中披露，相关信息可通过此链接获取。此外，执行副总裁 Nicholas Donoghoe 在 8 月 5 日（星期二）出售了 13,295 股该公司的股票。股票以平均价格 198.51 美元出售，总交易额为 2,639,190.45 美元。交易后，该执行副总裁直接持有 58,247 股该公司的股票，价值约 11,562,611.97 美元。这代表其持仓减少了 18.58%。该销售的披露信息可在此找到。公司内部人士持有该公司 0.25% 的股票。</p>
</div><h2>AbbVie Trading Up 0.4%</h2>
<div class="lb-trans"><h2>艾伯维股票上涨 0.4%</h2>
</div><ul>
<li>3 Biotech Giants Gaining From U.S. Sales and Policy Shifts</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家生物科技巨头受益于美国销售和政策变化</li>
</ul>
</div><p>AbbVie stock opened at $210.2840 on Friday. The stock has a market cap of $371.48 billion, a PE ratio of 100.14, a P/E/G ratio of 1.35 and a beta of 0.50. The stock has a 50-day moving average price of $192.84 and a 200 day moving average price of $192.96. AbbVie Inc. has a 52 week low of $163.81 and a 52 week high of $218.66. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14.</p>
<div class="lb-trans"><p>艾伯维股票在周五开盘价为 210.2840 美元。该股票的市值为 3714.8 亿美元，市盈率为 100.14，市盈增长比率为 1.35，贝塔值为 0.50。该股票的 50 日移动平均价格为 192.84 美元，200 日移动平均价格为 192.96 美元。艾伯维公司的 52 周最低价为 163.81 美元，52 周最高价为 218.66 美元。该公司的流动比率为 0.74，速动比率为 0.61，债务与股本比率为 44.14。</p>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $2.97 EPS for the quarter, missing analysts' consensus estimates of $3.24 by ($0.27). The company had revenue of $15.42 billion for the quarter, compared to analysts' expectations of $14.93 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.65 EPS. Equities research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>艾伯维（NYSE:ABBV - 获取免费报告）最近在 7 月 31 日（星期四）发布了季度财报。该公司报告季度每股收益为 2.97 美元，低于分析师一致预期的 3.24 美元（差额为 0.27 美元）。该公司季度收入为 154.2 亿美元，而分析师预期为 149.3 亿美元。艾伯维的股本回报率为 699.66%，净利润率为 6.45%。该公司季度收入较去年同期增长了 6.6%。在去年同期，该公司每股收益为 2.65 美元。股票研究分析师预测，艾伯维公司本财年的每股收益将达到 12.31 美元。</p>
</div><h2>AbbVie Dividend Announcement</h2>
<div class="lb-trans"><h2>艾伯维分红公告</h2>
</div><ul>
<li>If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>如果你想购买艾伯维但没有，现在仍然有时间购买</li>
</ul>
</div><p>The business also recently disclosed a quarterly dividend, which was paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th were paid a dividend of $1.64 per share. The ex-dividend date of this dividend was Tuesday, July 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.1%. AbbVie's dividend payout ratio is currently 312.38%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度分红，已于 8 月 15 日（星期五）支付。7 月 15 日（星期二）登记在册的股东获得每股 1.64 美元的分红。该分红的除息日期为 7 月 15 日（星期二）。这代表年化分红为 6.56 美元，分红收益率为 3.1%。艾伯维的分红支付比率目前为 312.38%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several research analysts have issued reports on the company. Daiwa America upgraded AbbVie from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, August 7th. Daiwa Capital Markets upgraded AbbVie from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and set a $214.00 price target for the company in a research report on Thursday, August 7th. Piper Sandler assumed coverage on AbbVie in a research report on Tuesday, August 12th. They issued an &#34;overweight&#34; rating and a $231.00 price target for the company. Bank of America raised their price target on AbbVie to $204.00 and gave the company a &#34;hold&#34; rating in a research report on Monday, June 9th. Finally, Citigroup raised their price target on AbbVie to $205.00 and gave the company a &#34;hold&#34; rating in a research report on Wednesday, June 11th. Five equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $214.95.</p>
<div class="lb-trans"><p>几位研究分析师对该公司发布了报告。大和美国在 8 月 7 日（星期四）的研究报告中将艾伯维的评级从 “持有” 上调至 “强力买入”。大和资本市场在 8 月 7 日（星期四）的研究报告中将艾伯维的评级从 “中性” 上调至 “跑赢大盘”，并为该公司设定了 214.00 美元的目标价。派珀·桑德勒在 8 月 12 日（星期二）的研究报告中开始覆盖艾伯维。他们给予 “增持” 评级，并为该公司设定了 231.00 美元的目标价。美国银行在 6 月 9 日（星期一）将艾伯维的目标价上调至 204.00 美元，并给予该公司 “持有” 评级。最后，花旗集团在 6 月 11 日（星期三）将艾伯维的目标价上调至 205.00 美元，并给予该公司 “持有” 评级。五位股票研究分析师对该股票给予了强力买入评级，十六位给予了买入评级，六位给予了持有评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 214.95 美元。</p>
</div><p><strong>Read Our Latest Research Report on AbbVie</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于艾伯维的最新研究报告</strong></p>
</div><h2>AbbVie Company Profile</h2>
<div class="lb-trans"><h2>艾伯维公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供的药物包括：Humira，用于治疗自身免疫性疾病和肠道贝赫切特病以及脓疱性坏死性皮肤病；Skyrizi，用于治疗中度至重度斑块型银屑病、银屑病性关节炎和克罗恩病；Rinvoq，用于治疗类风湿性关节炎、银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica，用于治疗成人血癌患者；Epkinly，用于治疗淋巴瘤；Elahere，用于治疗癌症；Venclexta/Venclyxto，用于治疗血癌。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than AbbVie</li>
<li>The Basics of Support and Resistance</li>
<li>Equal Weight ETFs: Hidden Upside in Today’s Market</li>
<li>5 Top Rated Dividend Stocks to Consider</li>
<li>Zillow Group Approaching Key Technical Levels: Is It Time to Buy?</li>
<li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li>
<li>For True Diversification: 3 Stocks You Can Buy Now</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比艾伯维更好的股票</li>
<li>支撑与阻力的基础知识</li>
<li>等权重 ETF：当今市场的隐藏上行空间</li>
<li>5 只值得考虑的高评级分红股票</li>
<li>Zillow Group 接近关键技术水平：是时候买入了吗？</li>
<li>异常交易量的股票：如何实时找到异常交易量股票</li>
<li>真正的多元化：现在可以购买的 3 只股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in AbbVie Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑艾伯维之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前买入……而艾伯维并不在名单上。</p>
</div><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Broadleaf Partners LLC 出售了艾伯维公司 $ABBV 的股票